BRIEFING
Cyclobenzaprine Hydrochloride Extended-Release Capsules. This proposal is based on the version of the monograph official as of May 1, 2020. The following changes are being proposed:
-
Replace the IR spectral agreement test in Identification A with a test based on UV spectral agreement using the proposed Assay to eliminate the use of methylene chloride.
-
Revise the Assay as follows:
-
Revise the Detector in the Chromatographic system to support the proposed Identification A.
-
Update the Chromatographic system to include Run time.
-
-
Revise the test for Organic Impurities as follows:
-
Add a table and update the Note in the System suitability section to present relative retention times as an aid in peak assignment.
-
Revise Table 3 to list only the limits for any unspecified degradation product and total degradation products.
-
In the Acceptance criteria, add a reference to User-Determined Reporting Thresholds 〈477〉 for user flexibility.
-
Update the cyproheptadine related compound B name to dibenzocycloheptenone.
-
-
Update the USP Reference Standards section to be consistent with current chemical information.
Additionally, minor editorial changes have been made to update the monograph to current USP style.
(SM4: G. Daddala)
Case ID—SUB-2202
USP REFERENCE STANDARDS FOR PURCHASE
USP Amitriptyline Hydrochloride RSUSP Cyclobenzaprine Hydrochloride RS
